Arrowhead Pharmaceuticals Inc.

Company Overview

Arrowhead Pharmaceuticals, focus primarily on the development of medications aimed at treating intractable diseases by suppressing the genes responsible for them. Utilizing a diverse array of RNA chemistries and efficient delivery methods, the company’s therapies activate the RNA interference mechanism to achieve swift, profound, and enduring suppression of target genes. Leveraging this innate pathway of gene silencing, the company’s RNAi-based therapeutics are designed to selectively target and deactivate specific disease-causing genes.

The company conducts its research and development endeavors, which include the progression of RNA interference (RNAi) therapeutics, at laboratory facilities situated in California and Wisconsin. The company focuses on therapeutic areas such as cardiometabolic, pulmonary, liver, neuromuscular and other areas. The company has 14 clinical stage programs of which 9 are wholly owned and 5 are partnered. Among the company’s current pipeline of products are Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), ARO-RAGE, ARO-MUC5AC, ARO-MMP7, and GSK-4532990.

Financial Highlights (FY 2024)

Company's Business Segments

• Cardiometabolic : Severe Hypertriglyceridemia, Dyslipidemia, Cardiovascular Disease.
• Pulmonary : Inflammatory Pulmonary Diseases, Muco-obstructive, Idiopathic Pulmonary Fibrosis.